JP2012513467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513467A5 JP2012513467A5 JP2011543601A JP2011543601A JP2012513467A5 JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5 JP 2011543601 A JP2011543601 A JP 2011543601A JP 2011543601 A JP2011543601 A JP 2011543601A JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5
- Authority
- JP
- Japan
- Prior art keywords
- resistant
- bacterium
- pharmaceutical composition
- clostridium difficile
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 241000193163 Clostridioides difficile Species 0.000 claims 10
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical group C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 8
- 229960005484 Daptomycin Drugs 0.000 claims 8
- 108010013198 Daptomycin Proteins 0.000 claims 8
- 230000003115 biocidal Effects 0.000 claims 8
- 206010060945 Bacterial infection Diseases 0.000 claims 6
- 101700016515 ATF5 Proteins 0.000 claims 4
- 101700033521 AZI2 Proteins 0.000 claims 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 102100016960 NCKAP1 Human genes 0.000 claims 4
- 101710036978 NCKAP1 Proteins 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- 229940076185 Staphylococcus aureus Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 2
- 229940049954 Penicillin Drugs 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 229960003165 Vancomycin Drugs 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229960000626 benzylpenicillin Drugs 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 C*(C)c(cc1)ccc1C(C)=CC(C)=O Chemical compound C*(C)c(cc1)ccc1C(C)=CC(C)=O 0.000 description 1
Claims (26)
- 式（Ｉ）：
ｖは、３〜７の整数である]
の化合物またはその薬学的に許容される塩。 - 式（ＩＩ）：
- 請求項２に記載の化合物またはその薬学的に許容される塩と、薬学的に許容される担体と、を含む医薬組成物。
- 処置を必要とする対象における、細菌感染症を処置または予防するための、請求項３に記載の医薬組成物。
- 対象が、ヒト、動物、細胞培養物または植物である、請求項４に記載の医薬組成物。
- 対象がヒトである、請求項５に記載の医薬組成物。
- 細菌感染症がグラム陽性菌によって引き起こされるものである、請求項４に記載の医薬組成物。
- 細菌が、クロストリジウム・ディフィシル株である、請求項７に記載の医薬組成物。
- クロストリジウム・ディフィシル株が、Ｎａｐ１ クロストリジウム・ディフィシル株である、請求項８に記載の医薬組成物。
- 細菌が抗生物質耐性菌である、請求項７に記載の医薬組成物。
- 抗生物質耐性菌が、ダプトマイシン耐性黄色ブドウ球菌、ダプトマイシン耐性フェシウム菌、ダプトマイシン耐性大便連鎖球菌、メチシリン耐性黄色ブドウ球菌、または、少なくとも１種の抗生物質耐性菌を含む細菌の混合である、請求項１０に記載の医薬組成物。
- 抗生物質耐性菌が、バンコマイシン、メチシリン、グリコペプチド抗生物質、ペニシリンまたはダプトマイシンに耐性である、請求項１０に記載の医薬組成物。
- 細菌感染症が、クロストリジウム・ディフィシル関連疾患(ＣＤＡＤ)である、請求項７に記載の医薬組成物。
- クロストリジウム・ディフィシル関連疾患が、Ｎａｐ１ クロストリジウム・ディフィシル感染から生じるか、またはこれによって悪化する、請求項１３に記載の医薬組成物。
- 対象において細菌感染症を処置するための医薬の製造における、請求項２に記載の化合物の使用。
- 対象が、ヒト、動物、細胞培養物または植物から選択される、請求項１５に記載の使用。
- 対象がヒトである、請求項１６に記載の使用。
- 細菌感染症がグラム陽性菌によって引き起こされるものである、請求項１５に記載の使用。
- 細菌が、クロストリジウム・ディフィシル株である、請求項１８に記載の使用。
- クロストリジウム・ディフィシル株が、Ｎａｐ１ クロストリジウム・ディフィシル株である、請求項１９に記載の使用。
- 細菌が抗生物質耐性菌である、請求項１８に記載の使用。
- 抗生物質耐性菌が、ダプトマイシン耐性黄色ブドウ球菌、ダプトマイシン耐性フェシウム菌、ダプトマイシン耐性大便連鎖球菌、メチシリン耐性黄色ブドウ球菌、または、少なくとも１種の抗生物質耐性菌を含む細菌の混合である、請求項１７に記載の使用。
- 抗生物質耐性菌が、バンコマイシン、メチシリン、グリコペプチド抗生物質、ペニシリンまたはダプトマイシンに耐性である、請求項２２に記載の使用。
- 細菌感染症がクロストリジウム・ディフィシル関連疾患(ＣＤＡＤ)である、請求項１８に記載の使用。
- クロストリジウム・ディフィシル関連疾患が、Ｎａｐ１ クロストリジウム・ディフィシル感染から生じるか、またはこれによって悪化する、請求項２４に記載の使用。
- 化合物が、下記式：
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13987508P | 2008-12-22 | 2008-12-22 | |
| US61/139,875 | 2008-12-22 | ||
| PCT/US2009/068747 WO2010075215A1 (en) | 2008-12-22 | 2009-12-18 | Novel antibacterial agents for the treatment of gram positive infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513467A JP2012513467A (ja) | 2012-06-14 |
| JP2012513467A5 true JP2012513467A5 (ja) | 2013-10-03 |
| JP5670914B2 JP5670914B2 (ja) | 2015-02-18 |
Family
ID=41718893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543601A Expired - Fee Related JP5670914B2 (ja) | 2008-12-22 | 2009-12-18 | グラム陽性菌感染症を処置するための新規抗菌剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8507647B2 (ja) |
| EP (2) | EP2379580B1 (ja) |
| JP (1) | JP5670914B2 (ja) |
| KR (1) | KR101717795B1 (ja) |
| CN (1) | CN102325787B (ja) |
| AR (1) | AR074833A1 (ja) |
| AU (1) | AU2009330245C1 (ja) |
| BR (1) | BRPI0923567A2 (ja) |
| CA (1) | CA2747965C (ja) |
| CY (1) | CY1114883T1 (ja) |
| DK (1) | DK2379580T3 (ja) |
| ES (1) | ES2442167T3 (ja) |
| HK (1) | HK1161886A1 (ja) |
| HR (1) | HRP20131170T1 (ja) |
| IL (1) | IL213638A0 (ja) |
| MX (1) | MX2011006803A (ja) |
| NZ (1) | NZ594019A (ja) |
| PL (1) | PL2379580T3 (ja) |
| PT (1) | PT2379580E (ja) |
| RS (1) | RS53152B (ja) |
| RU (1) | RU2512396C2 (ja) |
| SG (1) | SG172299A1 (ja) |
| SI (1) | SI2379580T1 (ja) |
| SM (1) | SMT201400037B (ja) |
| TW (1) | TWI444198B (ja) |
| WO (1) | WO2010075215A1 (ja) |
| ZA (1) | ZA201104693B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2837174A1 (en) * | 2011-05-26 | 2012-11-29 | Cubist Pharmaceuticals, Inc. | Cb-183,315 compositions and related methods |
| US10377699B2 (en) * | 2013-11-06 | 2019-08-13 | The University Of Hong Kong | Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue |
| WO2015172047A1 (en) * | 2014-05-08 | 2015-11-12 | Merck Sharp & Dohme Corp. | Cyclic peptide compounds and related methods, salts and compositions |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US11667674B2 (en) * | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| TWI742074B (zh) * | 2016-04-22 | 2021-10-11 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
| US10098890B2 (en) | 2016-10-29 | 2018-10-16 | Cipla Limited | Stable carfilzomib formulations |
| IT201600127655A1 (it) * | 2016-12-16 | 2018-06-16 | Gnosis Spa | Processo per la purificazione di antibiotici lipopolipeptidici |
| US10072045B1 (en) | 2017-06-26 | 2018-09-11 | Ramapo Pharmaceuticals, Inc. | Antibacterial lipopeptides and methods for their preparation and use |
| US10526343B2 (en) | 2018-03-26 | 2020-01-07 | University Of Sharjah | Heterocyclic systems and pharmaceutical applications thereof |
| RU2762182C1 (ru) * | 2020-12-08 | 2021-12-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" | Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| DE3376424D1 (en) | 1982-02-27 | 1988-06-01 | Beecham Group Plc | Antibacterial 1-normon-2-yl-heterocyclic compounds |
| IL68700A0 (en) | 1982-05-21 | 1983-09-30 | Lilly Co Eli | Improvements relating to a-21978c cyclic peptide derivatives and their production |
| USRE32311E (en) * | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4399067A (en) | 1982-05-21 | 1983-08-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4396543A (en) * | 1982-05-21 | 1983-08-02 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CN1013120B (zh) | 1984-10-09 | 1991-07-10 | 伊莱利利公司 | A-21978c衍生物生产方法改进 |
| CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
| US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| DE69121018T2 (de) | 1990-06-07 | 1996-12-19 | Lilly Co Eli | Lipopeptid Deacylase |
| WO1995005384A1 (en) | 1993-08-13 | 1995-02-23 | Smithkline Beecham Plc | Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity |
| DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| JP3123078B2 (ja) | 1996-03-08 | 2001-01-09 | 藤沢薬品工業株式会社 | 環状リポペプチド物質の脱アシル化法 |
| DE19807972A1 (de) | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
| US6468967B1 (en) | 1998-09-25 | 2002-10-22 | Cubist Pharmaceuticals, Incorporated | Methods for administration of antibiotics |
| JP2003520353A (ja) | 1999-11-03 | 2003-07-02 | ザ ウィタカー コーポレーション | マルチファイバアレー用光電子モジュール |
| KR20020063228A (ko) | 1999-12-15 | 2002-08-01 | 큐비스트 파마슈티컬즈 인코포레이티드 | 항균제로서 리포펩티드 |
| AU784755B2 (en) | 1999-12-15 | 2006-06-08 | Merck Sharp & Dohme Corp. | Daptomycin Analogs as antibacterial agents |
| CA2394313A1 (en) | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Novel lipopeptides as antibacterial agents |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1423414A4 (en) | 2001-08-06 | 2005-11-30 | Cubist Pharm Inc | NEW DEPSIPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF |
| BRPI0517830A (pt) * | 2004-11-12 | 2008-10-21 | Cubist Pharm Inc | lipopeptìdeos antiinfecciosos |
-
2009
- 2009-12-18 JP JP2011543601A patent/JP5670914B2/ja not_active Expired - Fee Related
- 2009-12-18 CA CA2747965A patent/CA2747965C/en not_active Expired - Fee Related
- 2009-12-18 SI SI200930815T patent/SI2379580T1/sl unknown
- 2009-12-18 SG SG2011045440A patent/SG172299A1/en unknown
- 2009-12-18 MX MX2011006803A patent/MX2011006803A/es active IP Right Grant
- 2009-12-18 WO PCT/US2009/068747 patent/WO2010075215A1/en active Application Filing
- 2009-12-18 RS RS20140021A patent/RS53152B/en unknown
- 2009-12-18 EP EP09795876.3A patent/EP2379580B1/en active Active
- 2009-12-18 AU AU2009330245A patent/AU2009330245C1/en not_active Ceased
- 2009-12-18 EP EP13183732.0A patent/EP2674437A1/en not_active Withdrawn
- 2009-12-18 US US12/641,465 patent/US8507647B2/en active Active
- 2009-12-18 NZ NZ594019A patent/NZ594019A/xx not_active IP Right Cessation
- 2009-12-18 ES ES09795876.3T patent/ES2442167T3/es active Active
- 2009-12-18 CN CN200980157145.XA patent/CN102325787B/zh not_active Expired - Fee Related
- 2009-12-18 PL PL09795876T patent/PL2379580T3/pl unknown
- 2009-12-18 PT PT97958763T patent/PT2379580E/pt unknown
- 2009-12-18 DK DK09795876.3T patent/DK2379580T3/da active
- 2009-12-18 BR BRPI0923567A patent/BRPI0923567A2/pt not_active Application Discontinuation
- 2009-12-18 RU RU2011130278/04A patent/RU2512396C2/ru not_active IP Right Cessation
- 2009-12-18 KR KR1020117017003A patent/KR101717795B1/ko active IP Right Grant
- 2009-12-21 TW TW098143962A patent/TWI444198B/zh not_active IP Right Cessation
- 2009-12-21 AR ARP090105021A patent/AR074833A1/es unknown
-
2011
- 2011-06-19 IL IL213638A patent/IL213638A0/en unknown
- 2011-06-24 ZA ZA2011/04693A patent/ZA201104693B/en unknown
-
2012
- 2012-03-09 HK HK12102426.6A patent/HK1161886A1/xx not_active IP Right Cessation
-
2013
- 2013-06-12 US US13/916,402 patent/US20140073558A1/en not_active Abandoned
- 2013-12-10 HR HRP20131170AT patent/HRP20131170T1/hr unknown
-
2014
- 2014-01-09 CY CY20141100015T patent/CY1114883T1/el unknown
- 2014-03-28 SM SM201400037T patent/SMT201400037B/xx unknown
-
2015
- 2015-08-04 US US14/818,123 patent/US20150337013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513467A5 (ja) | ||
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| JP2017519730A5 (ja) | ||
| Marsilio et al. | Coagulase-positive and coagulase-negative Staphylococci animal diseases | |
| Bell et al. | Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008) | |
| MX2007009059A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos. | |
| RU2004118716A (ru) | Лечение инфекции, вызываемой микроорганизмами | |
| AR073917A1 (es) | Sinergismo antibiotico | |
| Kazemi et al. | Antibacterial effect of silver nanoparticles along with protein synthesis-inhibiting antibiotics on Staphylococcus aureus isolated from cattle mastitis | |
| TW200510541A (en) | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof | |
| WO2013041663A3 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| KR20120038698A (ko) | 항생제 저항성 포도상구균(ｍｒｓａ)억제 유산균 바이셀라 비리데센스 | |
| JP2024009968A5 (ja) | ||
| JP2015522040A5 (ja) | ||
| JP2017533177A5 (ja) | ||
| CN103880930A (zh) | 万古霉素类衍生物及其制备方法和药用用途 | |
| Hussain et al. | Resistance pattern of 3rd generation cephalosporins | |
| CN109620827B (zh) | 杂环丙烯酮类化合物作为抗菌剂的用途 | |
| Jung et al. | Antibacterial activity of LCB01-0062, a novel oxazolidinone | |
| WO2009124086A3 (en) | Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections | |
| Nagy et al. | In vitro activity of daptomycin-metronidazole combinations against mixed bacterial cultures: reduced activity of metronidazole against Bacteroides species in the presence of Enterococcus faecalis | |
| JP6626516B2 (ja) | 抗菌組成物及び方法 | |
| Abdal et al. | Prevalence of genes encoding aminoglycoside resistant in methicillin-sensitive Staphylococcus aurous and coagulase-negative staphylococci isolated from hospital infectious. | |
| Mokrozub et al. | Antistaphylococcal action of lacto-and bifidobacteria and interleukin-2 | |
| Leite et al. | N-acetylcysteine and vancomycin alone and in combination against staphylococci biofilm |